(3-溴苯基)(哌嗪-1-基)甲酮 | 1016819-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-溴苯基)(哌嗪-1-基)甲酮
• 英文名称: 3-bromobenzoylpiperazine
• 英文别名: (3-bromophenyl)(piperazin-1-yl)methanone；(3-bromophenyl)-piperazin-1-ylmethanone
• CAS: 1016819-18-3
• 化学式: C₁₁H₁₃BrN₂O
• mdl: MFCD09037860
• 分子量: 269.141
• InChiKey: NIWDJNXTGZQJFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  (3-溴苯基)(哌嗪-1-基)甲酮 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 34.0h， 生成 2-(4-(3-bromobenzoyl)piperazin-1-yl)-1-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piperazin-1-yl)ethan-1-one
  参考文献：
  名称：

  Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer’s disease

  摘要：

  During the last decade, the one drug-one target strategy has resulted to be inefficient in facing diseases with complex ethiology like Alzheimer's disease and many others. In this context, the multitarget paradigm has emerged as a promising strategy. Based on this consideration, we aim to develop novel molecules as promiscuous ligands acting in two or more targets at the same time. For such purpose, a new series of indolylpropyl-piperazinyl oxoethyl-benzamido piperazines were synthesized and evaluated as multitarget-directed drugs for the serotonin transporter (SERT) and acetylcholinesterase (AChE). The ability to decrease beta-amyloid levels as well as cell toxicity of all compounds were also measured. In vitro results showed that at least four compounds displayed promising activity against SERT and AChE. Compounds 18 and 19 (IC50 = 3.4 and 3.6 mu M respectively) exhibited AChE inhibition profile in the same order of magnitude as donepezil (DPZ, IC50 = 2.17 mu M), also displaying nanomolar affinity in SERT. Moreover, compounds 17 and 24 displayed high SERT affinities (IC50 = 9.2 and 1.9 nM respectively) similar to the antidepressant citalopram, and significant micromolar AChE activity at the same time. All the bioactive compounds showed a low toxicity profile in the range of concentrations studied. Molecular docking allowed us to rationalize the binding mode of the synthesized compounds in both targets. In addition, we also show that compounds 11 and 25 exhibit significant beta-amyloid lowering activity in a cell-based assay, 11 (50% inhibition, 10 mu M) and 25 (35% inhibition, 10 mu M).These results suggest that indolylpropyl benzamidopiperazines based compounds constitute promising leads for a multitargeted approach for Alzheimers disease. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112368
• 作为产物：
  描述：

  间溴苯甲酸 在 氯化亚砜 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 (3-溴苯基)(哌嗪-1-基)甲酮
  参考文献：
  名称：

  研究一些呋喃烷衍生物作为潜在的NO供体的合成和心血管活性。

  摘要：

  设计了一系列结合了呋喃喃和尼可地尔部分的杂合分子，作为具有心血管和脑血管活性的潜在NO供体。通过常规方法成功合成了36个目标分子，并通过红外光谱，1H-NMR光谱和高分辨率质谱进行了表征。测试了这些化合物对KCl诱导的内皮剥落的兔胸主动脉收缩的作用。发现有8种化合物在10 microM时可减少KCl诱导的收缩超过30％。这些化合物之一以外的所有化合物的特征在于，在苯环中存在通过酰胺或酯键与呋喃喃部分连接的吸电子基团。末端羰基键（酯或酰胺）的性质以及桥接两个羰基官能团的烷基链的长度或类型对活性几乎没有影响。测试了一种活性化合物N-（4-甲氧基-苯甲酰基）-N'-[3-甲基呋喃基-4-羰基）哌嗪（17i）在1.5 mg / kg时对麻醉大鼠的降压作用，并发现逐渐和持续的降压作用。结果表明，呋喃根-尼可地尔衍生物是设计用于高血压的NO供体化合物的有用线索。

  DOI：

  10.1248/cpb.48.808

文献信息

• Discovery of a Novel Mycobacterial F‐ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines
  作者：Adam Hotra、Priya Ragunathan、Pearly Shuyi Ng、Pattarakiat Seankongsuk、Amaravadhi Harikishore、Jickky Palmae Sarathy、Wuan‐Geok Saw、Umayal Lakshmanan、Patcharaporn Sae‐Lao、Nitin Pal Kalia、Joon Shin、Revathy Kalyanasundaram、Sivaraj Anbarasu、Krupakar Parthasarathy、Chaudhari Namrata Pradeep、Harshyaa Makhija、Peter Dröge、Anders Poulsen、Jocelyn Hui Ling Tan、Kevin Pethe、Thomas Dick、Roderick W. Bates、Gerhard Grüber

  DOI：10.1002/anie.202002546

  日期：2020.8.3

  that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug‐ as well as bedaquiline‐resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity

  F 1 F O -ATP合酶是结核分枝杆菌生长和生存力所必需的并且是经过验证的临床目标。酶旋转γ亚基的分枝杆菌特异性环在酶复合物中ATP合成的偶联中起作用。我们报告发现了针对这种γ亚基环的新型抗分枝杆菌GaMF1的发现。生化和NMR研究表明，GaMF1通过与环结合来抑制ATP合酶活性。GaMF1具有杀菌作用，对多药耐药和苯达喹啉耐药菌株具有活性。在支架上的化学努力揭示了动态结构活性关系，并提供了具有纳摩尔浓度的类似物。GaMF1与苯达喹啉或新型二芳基喹啉类似物的结合在人胚胎干细胞报告基因分析中显示出增强作用，而不会引起基因毒性或表型变化。
• Synthesis and positive inotropic evaluation of [1,2,4]triazolo[3,4-a]phthalazine and tetrazolo[5,1-a]phthalazine derivatives bearing substituted piperazine moieties
  作者：Long-Xu Ma、Bai-Ri Cui、Yan Wu、Jia-Chun Liu、Xun Cui、Li-Ping Liu、Hu-Ri Piao

  DOI：10.1016/j.bmcl.2014.02.040

  日期：2014.4

  Four series of [1,2,4]triazolo[3,4-]phthalazine and tetrazolo[5,1-]phthalazine derivatives bearing substituted piperazine moieties were synthesized and evaluated for their positive inotropic activity by measuring the left atrium stroke volume in isolated rabbit-heart preparations. Several compounds were developed and showed favorable activities compared to the standard drug milrinone, with (4-([1,2

  合成了四个系列的带有取代哌嗪部分的[1,2,4]三唑并[3,4-]酞嗪和四唑并[5,1-]酞嗪衍生物，并通过测量分离的左心房搏出量来评估其正性肌力活性。兔心制剂。与标准药物米力农相比，开发了几种化合物，并显示出良好的活性，其中（4-（[1,2,4]三唑并[3,4-]酞嗪-6-基）哌嗪-1-基）（-甲苯基）甲酮 () 被认为是最有效的，浓度为 3×10M 时每搏输出量增加 19.15±0.22%（米力农：2.46±0.07%）。作用机制初步研究表明其正性肌力作用可能与PDE-cAMP-PKA信号通路有关。还根据变时作用评价表现出正性肌力作用的化合物。
• Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms
  作者：Francesca Mancuso、Anna Di Fiore、Laura De Luca、Andrea Angeli、Simona M. Monti、Giuseppina De Simone、Claudiu T. Supuran、Rosaria Gitto

  DOI：10.1021/acsmedchemlett.0c00062

  日期：2020.5.14

  biochemical evaluation of a series of substituted 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamides (5a-s) developed as inhibitors of druggable carbonic anhydrase (CA) isoforms, as tools for the identification of new therapeutics. X-ray crystallography confirmed that this class of benzenesulfonamides binds CAs through the canonical anchoring of the benzenesulfonamide moiety to the metal ion and a

  我们报告了一系列的取代的4-（4-芳酰基哌嗪-1-羰基）苯磺酰胺（5a-s）的合成和生化评估，这些药物被开发为可药用的碳酸酐酶（CA）亚型的抑制剂，作为鉴定新疗法的工具。X射线晶体学证实，这类苯磺酰胺通过苯磺酰胺部分对金属离子的典型锚定和活性中心腔中部/顶部区域的尾部介导识别而与CA结合。化合物5e（R = 2-Cl）对脑表达的hCA VII具有相关的选择性。对于抑制剂5o（R = 3-NO2），发现对肿瘤表达的hCA IX / hCA XII的结合亲和力和选择性优于无处不在的hCA I / hCA II的最佳平衡。
• NMR-based investigations of acyl-functionalized piperazines concerning their conformational behavior in solution
  作者：Robert Wodtke、Janine Steinberg、Martin Köckerling、Reik Löser、Constantin Mamat

  DOI：10.1039/c8ra09152h

  日期：——

  their conformational behavior using temperature-dependent 1H NMR spectroscopy. All investigated piperazines occur as conformers at room temperature resulting from the restricted rotation of the partial amide double bond. In the case of selected mono-N-benzoylated and unsymmetrically N,N′-substituted derivatives, the appearance of the 1H NMR spectrum was further shaped by the limited interconversion of

  合成了选定的N-苯甲酰化哌嗪化合物，并使用温度依赖性1 H NMR 光谱研究其构象行为。由于部分酰胺双键的旋转受限，所有研究的哌嗪在室温下均以构象异构体形式出现。在选定的单-N-苯甲酰化和不对称N , N'-取代衍生物的情况下， 1 H NMR谱的外观通过哌嗪椅构象的有限互变进一步形成。因此，确定了两个不同的聚结点T C，并且计算出它们产生的活化能垒 Δ G ‡介于 56 至 80 kJ mol -1之间。在大多数情况下，酰胺位点的T C和 Δ G ‡似乎高于环反转的相应值。通过与哈米特常数的相关性分析了取代基对旋转和反转势垒的影响。所获得的结果在文献数据的背景下进行讨论和解释。与游离仲胺相比，在胺位点连接的额外芳基取代基导致旋转和反转势垒减少。为了支持和证明 NMR 分析的结果，获得了选定哌嗪的单晶并进行了 XRD 分析。为了强调这一结果，对两种潜在的 TGase 2 抑制剂进行了研究，显示出具有相似值的能量势垒。
• Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
  作者：Hongyu Qin、Jian Zhang、Yilu Zhao、Lihui Zhang、Jinhong Feng、Lei Zhang

  DOI：10.3389/fphar.2022.1054616

  日期：——

  Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated and BRCA-unmutated cancers.Methods: Aiming to the discovery of olaparib analogs for the treatment of cancer, structural modifications were performed based on the

  简介：聚（ADP-核糖）聚合酶 (PARP) 抑制剂的开发已在癌症治疗中得到广泛研究。奥拉帕尼是第一个获批的 PARP 抑制剂，显示出抑制 BRCA（乳腺癌相关）突变和 BRCA 未突变癌症的效力。方法：为了发现用于治疗癌症的奥拉帕尼类似物，进行了基于奥拉帕尼的脚手架。在第一系列中，羰基还原为CH2个导致 PARP1 抑制活性降低。在保留原始羰基的情况下，通过引入酰肼和芳香族氮芥基团，衍生出具有强效 PARP1 抑制活性的分子。合成的化合物在 PARP1 酶抑制筛选、基于癌细胞的抗增殖测定、细胞周期停滞和细胞凋亡研究中进行了评估。的抗癌效力体外抗增殖试验。与奥拉帕尼和苯丁酸氮芥相比，分子 C2 在抑制多种 BRCA 未突变细胞系方面也表现出显着的效力。进一步分析揭示了 C2 在诱导 G2/M 期细胞周期停滞和促进细胞凋亡方面的作用。讨论：总的来说，奥拉帕尼-苯丁酸氮芥杂化分子 (C2) 可用作进一步药物设计的先导化合物。